litlas
ログインアカウント作成

Roy S. Herbst

1984–2025 年に発表

258
論文数
84,011
被引用数
134
h 指数
248
i10 指数

被引用数

Roy S. Herbst の年別被引用数1951 年: 被引用 1 件1971 年: 被引用 1 件1984 年: 被引用 1 件1985 年: 被引用 3 件1986 年: 被引用 7 件1987 年: 被引用 6 件1988 年: 被引用 15 件1989 年: 被引用 15 件1990 年: 被引用 23 件1991 年: 被引用 11 件1992 年: 被引用 6 件1993 年: 被引用 6 件1994 年: 被引用 1 件1995 年: 被引用 4 件1997 年: 被引用 3 件1998 年: 被引用 3 件1999 年: 被引用 3 件2000 年: 被引用 7 件2001 年: 被引用 26 件2002 年: 被引用 70 件2003 年: 被引用 135 件2004 年: 被引用 230 件2005 年: 被引用 490 件2006 年: 被引用 517 件2007 年: 被引用 496 件2008 年: 被引用 460 件2009 年: 被引用 584 件2010 年: 被引用 466 件2011 年: 被引用 470 件2012 年: 被引用 386 件2013 年: 被引用 504 件2014 年: 被引用 396 件2015 年: 被引用 621 件2016 年: 被引用 873 件2017 年: 被引用 871 件2018 年: 被引用 923 件2019 年: 被引用 2,672 件2020 年: 被引用 3,418 件2021 年: 被引用 3,972 件2022 年: 被引用 3,220 件2023 年: 被引用 2,401 件2024 年: 被引用 3,282 件2025 年: 被引用 1,538 件2026 年: 被引用 32 件1952〜1970 年は被引用が無いため表示していません1972〜1983 年は被引用が無いため表示していません1996 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 8,990 件、この内訳の 25.2%中国: 引用元論文 6,498 件、この内訳の 18.2%イタリア: 引用元論文 1,678 件、この内訳の 4.7%イギリス: 引用元論文 1,613 件、この内訳の 4.5%日本: 引用元論文 1,527 件、この内訳の 4.3%ドイツ: 引用元論文 1,440 件、この内訳の 4%フランス: 引用元論文 1,396 件、この内訳の 3.9%スペイン: 引用元論文 1,132 件、この内訳の 3.2%カナダ: 引用元論文 1,072 件、この内訳の 3%韓国: 引用元論文 888 件、この内訳の 2.5%オランダ: 引用元論文 831 件、この内訳の 2.3%オーストラリア: 引用元論文 777 件、この内訳の 2.2%
0%25.2%その他 22%

機関

分野

  • Medicine66.1%
  • Biochemistry, Genetics and Molecular Biology22.5%
  • Immunology and Microbiology5.8%
  • Engineering1.2%
  • Computer Science0.8%
  • Neuroscience0.7%
  • その他2.9%

トピック

  • Cancer Immunotherapy and Biomarkers11.6%
  • Lung Cancer Treatments and Mutations7.7%
  • Lung Cancer Research Studies3.8%
  • Immunotherapy and Immune Responses3.5%
  • Lung Cancer Diagnosis and Treatment3.3%
  • Cancer Genomics and Diagnostics2.7%
  • その他67.4%

共著者

全論文

検索で開く
  1. The biology and management of non-small cell lung cancer

    著者: Roy S. Herbst, Daniel Morgensztern, Chris Boshoff - Nature 2018 被引用: 5,055

  2. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

    著者: Roy S. Herbst, Paul Baas, Dong‐Wan Kim, Enriqueta Felip, José Luis Perez‐Gracia, Ji‐Youn Han, Julian R. Molina, Joo-Hang Kim, Catherine Dubos Arvis, Myung‐Ju Ahn, Margarita Majem, Mary J. Fidler, Gilberto de Castro, Marcelo Garrido, Gregory M. Lubiniecki, Yue Shentu, Ellie Im, Marisa Dolled‐Filhart, Edward B. Garon - The Lancet 2015 被引用: 6,537

  3. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

    著者: Roy S. Herbst, Jean‐Charles Soria, Marcin Kowanetz, Gregg Fine, Omid Hamid, Michael S. Gordon, Jeffery A. Sosman, David F. McDermott, John D. Powderly, Scott Gettinger, Holbrook E. Kohrt, Leora Horn, Donald P. Lawrence, Sandra Rost, Maya K. Leabman, Yuanyuan Xiao, Ahmad Mokatrin, Hartmut Koeppen, Priti S. Hegde, Ira Mellman, Daniel S. Chen, F. Stephen Hodi - Nature 2014 被引用: 5,302

  4. Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC

    著者: Roy S. Herbst, Giuseppe Giaccone, Filippo de Marinis, Niels Reinmuth, A. Vergnenègre, Carlos H. Barrios, Masahiro Morise, Enriqueta Felip, Zoran Andrić, Sarayut Lucien Geater, Mustafa Özgüroğlu, Wei Zou, Alan Sandler, Ida Enquist, Kimberly M. Komatsubara, Yu Deng, Hiroshi Kuriki, Xiaohui Wen, Mark L. McCleland, Simonetta Mocci, Jacek Jassem, David R. Spigel - New England Journal of Medicine 2020 被引用: 1,691

  5. Toward personalized treatment approaches for non-small-cell lung cancer

    著者: Meina Wang, Roy S. Herbst, Chris Boshoff - Nature Medicine 2021 被引用: 1,140

  6. Osimertinib in Resected EGFR -Mutated Non–Small-Cell Lung Cancer

    著者: Yi‐Long Wu, Masahiro Tsuboi, Jie He, Thomas John, Christian Grohé, Margarita Majem, Jonathan W. Goldman, К. К. Лактионов, Sang‐We Kim, Terufumi Kato, Huu-Vinh Vu, Shun Lü, Kye Young Lee, Charuwan Akewanlop, Chong‐Jen Yu, Filippo de Marinis, Laura Bonanno, Manuel Dómine, Frances A. Shepherd, Lingmin Zeng, Rachel Hodge, Ajlan Atasoy, Yuri Rukazenkov, Roy S. Herbst - New England Journal of Medicine 2020 被引用: 1,756

  7. Overall Survival with Osimertinib in Resected EGFR -Mutated NSCLC

    著者: Masahiro Tsuboi, Roy S. Herbst, Thomas John, Terufumi Kato, Margarita Majem, Christian Grohé, Jie Wang, Jonathan W. Goldman, Shun Lü, Wu‐Chou Su, Filippo de Marinis, Frances A. Shepherd, Ki Hyeong Lee, Nhieu Thi Le, Arunee Dechaphunkul, Dariusz M. Kowalski, Lynne Poole, Ana Bolanos, Yuri Rukazenkov, Yi‐Long Wu - New England Journal of Medicine 2023 被引用: 612

  8. Longitudinal analyses reveal immunological misfiring in severe COVID-19

    著者: Carolina Lucas, Patrick Wong, Jon Klein, Tiago B. R. Castro, Julio Silva, Maria E. Sundaram, Mallory K. Ellingson, Tianyang Mao, Ji Eun Oh, Benjamin Israelow, Takehiro Takahashi, Maria Tokuyama, Peiwen Lu, Arvind Venkataraman, Annsea Park, Subhasis Mohanty, Haowei Wang, Anne L. Wyllie, Chantal B. F. Vogels, Rebecca Earnest, Sarah Lapidus, Isabel M. Ott, Adam J. Moore, M. Catherine Muenker, John Fournier, Melissa Campbell, Camila D. Odio, Arnau Casanovas‐Massana, Yale IMPACT Team, Abeer Obaid, Alice Lu-Culligan, Allison Nelson, Anderson F. Brito, Ángela Núñez, Anjelica Martin, Annie Watkins, Bertie Geng, Chaney C. Kalinich, Christina A. Harden, Codruta Todeasa, Cole Jensen, Daniel Kim, David McDonald, Denise Shepard, Edward Courchaine, Elizabeth B. White, Eric Song, Erin Silva, Eriko Kudo, Giuseppe DeIuliis, Harold Rahming, Hong‐Jai Park, Irene Matos, Jessica Nouws, Jordan Valdez, Joseph R. Fauver, Joseph K. Lim, Kadi-Ann Rose, Kelly Anastasio, Kristina Brower, Laura Glick, Lokesh Sharma, Lorenzo R. Sewanan, Lynda Knaggs, Maksym Minasyan, Maria Batsu, Mary E. Petrone, Maxine Kuang, Maura Nakahata, Melissa Campbell, Melissa Linehan, Michael H. Askenase, Michael Simonov, Mikhail Smolgovsky, Nicole Sonnert, Nida Naushad, Pavithra Vijayakumar, Rick Martinello, Rupak Datta, Ryan Handoko, Santos Bermejo, Sarah Prophet, Sean Bickerton, Sofia Velazquez, Tara Alpert, Tyler Rice, William Khoury-Hanold, Xiaohua Peng, Yexin Yang, Yiyun Cao, Yvette Strong, Roy S. Herbst, Albert C. Shaw, Ruslan Medzhitov, Wade L. Schulz, Nathan D. Grubaugh, Charles S. Dela Cruz, Shelli Farhadian, Albert I. Ko, Saad B. Omer ほか 1 名 - Nature 2020 被引用: 2,319

  9. Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer

    著者: Scott Gettinger, Jungmin Choi, Katherine Hastings, Anna Truini, Ila Datar, Ryan Sowell, Anna Wurtz, Weilai Dong, Guoping Cai, Mary Ann Melnick, Victor Y. Du, Joseph Schlessinger, Sarah B. Goldberg, Anne C. Chiang, Miguel F. Sanmamed, Ignacio Melero, Jackeline Agorreta, Luis M. Montuenga, Richard P. Lifton, Soldano Ferrone, Paula Kavathas, David L. Rimm, Susan M. Kaech, Kurt A. Schalper, Roy S. Herbst, Katerina Politi - Cancer Discovery 2017 被引用: 755

  10. Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities

    著者: Tae Kon Kim, Esten N. Vandsemb, Roy S. Herbst, Lieping Chen - Nature Reviews Drug Discovery 2022 被引用: 347

  11. Co-occurring Genomic Alterations Define Major Subsets of KRAS -Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities

    著者: Ferdinandos Skoulidis, Lauren A. Byers, Lixia Diao, Vassiliki A. Papadimitrakopoulou, Pan Tong, Julie Izzo, Carmen Behrens, Humam Kadara, Edwin R. Parra, Jaime Rodriguez Canales, Jianjun Zhang, Uma Giri, Jayanthi Gudikote, María Angélica Cortez, Chao Yang, You-Hong Fan, Michael Peyton, Luc Girard, Kevin R. Coombes, Carlo Toniatti, Timothy P. Heffernan, Murim Choi, Garrett M. Frampton, Vincent A. Miller, John N. Weinstein, Roy S. Herbst, Kwok‐Kin Wong, Jianhua Zhang, Padmanee Sharma, Gordon B. Mills, Waun Ki Hong, John D. Minna, James P. Allison, P. Andrew Futreal, Jing Wang, Ignacio I. Wistuba, John V. Heymach - Cancer Discovery 2015 被引用: 916

  12. Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy

    著者: Jun Wang, Jingwei Sun, Linda N. Liu, Dallas B. Flies, Xinxin Nie, Maria Toki, Jianping Zhang, Chang Song, Melissa Zarr, Xu Zhou, Xue Han, Kristina A. Archer, Thomas O’Neill, Roy S. Herbst, Agedi Boto, Miguel F. Sanmamed, Solomon Langermann, David L. Rimm, Lieping Chen - Nature Medicine 2019 被引用: 697

  13. COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non–Small-Cell Lung Cancer

    著者: Roy S. Herbst, Margarita Majem, Fabrice Barlesi, Enric Carcereny, Quincy Chu, Isabelle Monnet, Alfredo Sanchez-Hernandez, Shaker Dakhil, D. Ross Camidge, Leanne Winzer, Yee Soo-Hoo, Zachary A. Cooper, Rakesh Kumar, John Bothos, Charu Aggarwal, Alex Martinez-Marti - Journal of Clinical Oncology 2022 被引用: 287

  14. Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial

    著者: Roy S. Herbst, Yi‐Long Wu, Thomas John, Christian Grohé, Margarita Majem, Jie Wang, Terufumi Kato, Jonathan W. Goldman, К. К. Лактионов, Sang‐We Kim, Chong‐Jen Yu, Hữu Vĩnh Vũ, Shun Lü, Kye Young Lee, Guzel Mukhametshina, Charuwan Akewanlop, Filippo de Marinis, Laura Bonanno, Manuel Dómine, Frances A. Shepherd, Damien Urban, Xiangning Huang, Ana Bolanos, Marta Stachowiak, Masahiro Tsuboi - Journal of Clinical Oncology 2023 被引用: 389

  15. Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial

    著者: Sarah B. Goldberg, Kurt A. Schalper, Scott Gettinger, Amit Mahajan, Roy S. Herbst, Anne C. Chiang, Rogério Lilenbaum, Frederick H. Wilson, Sacit Bulent Omay, James B. Yu, Lucia B. Jilaveanu, Thuy Tran, Kira F. Pavlik, Elin Rowen, Heather Gerrish, Annette Komlo, Richa Gupta, Hailey Wyatt, Matthew Ribeiro, Yuval Kluger, Geyu Zhou, Wei Wei, Veronica Chiang, Harriet M. Kluger - The Lancet Oncology 2020 被引用: 538

  16. An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance

    著者: Lauren A. Byers, Lixia Diao, Jing Wang, Pierre Saintigny, Luc Girard, Michael Peyton, Li Shen, You-Hong Fan, Uma Giri, Praveen K. Tumula, Monique B. Nilsson, Jayanthi Gudikote, Hai T. Tran, Robert J. Cardnell, David J. Bearss, Steven L. Warner, Jason M. Foulks, Steven B. Kanner, Varsha Gandhi, Nancy Krett, Steven T. Rosen, Edward S. Kim, Roy S. Herbst, George R. Blumenschein, J. Jack Lee, Scott M. Lippman, K. Kian Ang, Gordon B. Mills, Waun Ki Hong, John N. Weinstein, Ignacio I. Wistuba, Kevin R. Coombes, John D. Minna, John V. Heymach - Clinical Cancer Research 2012 被引用: 1,121

  17. Systematic Immunotherapy Target Discovery Using Genome-Scale In Vivo CRISPR Screens in CD8 T Cells

    著者: Matthew B. Dong, Guangchuan Wang, Ryan D. Chow, Lupeng Ye, Lvyun Zhu, Xiaoyun Dai, Jonathan J. Park, Hyunu R. Kim, Youssef Errami, Christopher D. Guzman, Xiaoyu Zhou, Krista Y. Chen, Paul Renauer, Yaying Du, Johanna Shen, Stanley Z. Lam, J. Zhou, Donald R. Lannin, Roy S. Herbst, Sidi Chen - Cell 2019 被引用: 328

  18. Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer

    著者: Arvind Ravi, Matthew D. Hellmann, Monica Arniella, Mark Holton, Samuel S. Freeman, Vivek Naranbhai, Chip Stewart, Ignaty Leshchiner, Jaegil Kim, Yo Akiyama, Aaron T. Griffin, Natalie I. Vokes, Mustafa Sakhi, Vashine Kamesan, Hira Rizvi, Biagio Ricciuti, Patrick M. Forde, Valsamo Anagnostou, Jonathan W. Riess, Don L. Gibbons, Nathan A. Pennell, Vamsidhar Velcheti, Subba R. Digumarthy, Mari Mino–Kenudson, Andrea Califano, John V. Heymach, Roy S. Herbst, Julie R. Brahmer, Kurt A. Schalper, Victor E. Velculescu, Brian S. Henick, Naiyer A. Rizvi, Pasi A. Jänne, Mark M. Awad, Andrew Chow, Benjamin D. Greenbaum, Marta Łuksza, Alice T. Shaw, Jedd D. Wolchok, Nir Hacohen, Gad Getz, Justin F. Gainor - Nature Genetics 2023 被引用: 186

  19. Lung Cancer

    著者: Roy S. Herbst, John V. Heymach, Scott M. Lippman - New England Journal of Medicine 2008 被引用: 2,390

  20. Immunotherapy in Non–Small Cell Lung Cancer: Facts and Hopes

    著者: Deborah B. Doroshow, Miguel F. Sanmamed, Katherine Hastings, Katerina Politi, David L. Rimm, Lieping Chen, Ignacio Melero, Kurt A. Schalper, Roy S. Herbst - Clinical Cancer Research 2019 被引用: 718

  21. Review of epidermal growth factor receptor biology

    著者: Roy S. Herbst - International Journal of Radiation Oncology*Biology*Physics 2004 被引用: 1,404

  22. Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non–Small-Cell Lung Cancer Previously Treated With Immunotherapy—Lung-MAP S1800A

    著者: Karen L. Reckamp, Mary W. Redman, Konstantin H. Dragnev, Katherine Minichiello, Liza C. Villaruz, Bryan A. Faller, Tareq Al Baghdadi, Susan J. Hines, Leah Everhart, Louise Highleyman, Vassiliki A. Papadimitrakopoulou, Joel W. Neal, Saiama N. Waqar, Jyoti D. Patel, Jhanelle E. Gray, David R. Gandara, Karen Kelly, Roy S. Herbst - Journal of Clinical Oncology 2022 被引用: 240

  23. Immune Cell PD-L1 Colocalizes with Macrophages and Is Associated with Outcome in PD-1 Pathway Blockade Therapy

    著者: Yuting Liu, Jon Zugazagoitia, Fahad Shabbir Ahmed, Brian S. Henick, Scott Gettinger, Roy S. Herbst, Kurt A. Schalper, David L. Rimm - Clinical Cancer Research 2019 被引用: 337

  24. Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1–Positive Advanced NSCLC

    著者: Roy S. Herbst, Edward B. Garon, Dong‐Wan Kim, Byoung Chul Cho, Radj Gervais, José Luis Perez‐Gracia, Ji‐Youn Han, Margarita Majem, Martin Förster, I. Monnet, Silvia Novello, Matthew A. Gubens, Michael Boyer, Wu‐Chou Su, Ayman Samkari, Erin Jensen, Julie Kobie, Bilal Piperdi, Paul Baas - Journal of Thoracic Oncology 2021 被引用: 312